In conclusion, this study demonstrates that supplementation with LAH efficiently inhibits fatty liver development and hepatotoxicity in HFD-induced NAFLD and prevents abnormal lipid accumulation by regulating AMPK/ACC activation, increasing β-oxidation, and downregulating FAS and SREBP1. This evidence concerns the gene SREBF1 and metabolic dysfunction-associated steatotic liver disease.